SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001447028-20-000027
Filing Date
2020-02-19
Accepted
2020-02-19 08:03:32
Documents
1
Period of Report
2020-02-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_158211739512646.html 4  
1 FORM 4 wf-form4_158211739512646.xml 4 3874
  Complete submission text file 0001447028-20-000027.txt   5418
Mailing Address C/O ARBUTUS BIOPHARMA 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address
HASTINGS DAVID C (Reporting) CIK: 0001237401 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34949 | Film No.: 20627446

Mailing Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8 604-419-3200
Arbutus Biopharma Corp (Issuer) CIK: 0001447028 (see all company filings)

IRS No.: 980597776 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations